Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:317 | Altered, Cardiovascular development/function |
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.25 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal System Disease | Under Development | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory System Disease | Under Development | 0.4 | KE:1496 | Increased, secretion of proinflammatory mediators |
KE:272 | Activation/Proliferation, T-cells | |||||
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.4 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | |||||
AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.06 | KE:458 | Increased, De Novo FA synthesis |
AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive System Disease | - | 0.14 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.08 | KE:531 | Decreased, LH Surge |
AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.17 | KE:768 | Increase, Cytotoxicity |
AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory System Disease | - | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | |||||
AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | 0.33 | KE:777 | Increase, Inflammation (corneal cells) |
KE:778 | Increase, Regenerative cell proliferation (corneal cells) | |||||
AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | 0.4 | KE:149 | Increase, Inflammation |
KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | |||||
AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | Under Development | 0.25 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.25 | KE:787 | Increase, Regenerative cell proliferation (hepatocytes) |
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | |||||
AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary System Disease | - | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.08 | KE:531 | Decreased, LH Surge |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.29 | KE:768 | Increase, Cytotoxicity |
KE:870 | Increase, Cell Proliferation | |||||
AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal System Disease | Under Review | 0.33 | KE:1494 | Leukocyte recruitment/activation |
KE:68 | Accumulation, Collagen | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.14 | KE:317 | Altered, Cardiovascular development/function |
AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive System Disease | - | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.14 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | WPHA/WNT Endorsed | 0.38 | KE:68 | Accumulation, Collagen |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:149 | Increase, Inflammation |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.38 | KE:1281 | Increased, DNA Damage-Repair |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1262 | Apoptosis | |||||
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.33 | KE:1262 | Apoptosis |
KE:1503 | Histone acetylation, increase | |||||
AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.2 | KE:1394 | Induction, persistent proliferation/sustained proliferation |
AOP:237 | Substance interaction with lung resident cell membrane components leading to atherosclerosis | Cardiovascular System Disease | Under Development | 0.2 | KE:1496 | Increased, secretion of proinflammatory mediators |
AOP:241 | Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.17 | KE:68 | Accumulation, Collagen |
AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.29 | KE:870 | Increase, Cell Proliferation |
KE:155 | Inadequate DNA repair | |||||
AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural Tube Defect | - | 0.2 | KE:1503 | Histone acetylation, increase |
AOP:277 | Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response | Immune System Disease | WPHA/WNT Endorsed | 0.25 | KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) |
AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal System Disease; Respiratory System Disease | - | 0.14 | KE:149 | Increase, Inflammation |
AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1771 | Decrease, Adenosine triphosphate pool |
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1771 | Decrease, Adenosine triphosphate pool |
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.2 | KE:155 | Inadequate DNA repair |
AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.43 | KE:1115 | Increase, Reactive oxygen species |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:870 | Increase, Cell Proliferation | |||||
AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:315 | Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response | Immune System Disease | Under Development | 0.2 | KE:1716 | Blockade of STAT5 phosphorylation |
AOP:320 | Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality | Unclassified | Under Development | 0.33 | KE:1847 | Increased SARS-CoV-2 production |
KE:1750 | Increased inflammatory immune responses | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.18 | KE:10041 | Altered metabolic rate |
KE:10042 | Abnormal development | |||||
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.2 | KE:155 | Inadequate DNA repair |
AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | 0.17 | KE:807 | Decreased, cholesterol |
AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary System Disease | - | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
AOP:362 | Immune mediated hepatitis | Gastrointestinal System Disease; Immune System Disease | - | 0.12 | KE:1633 | Increase in inflammation |
AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1877 | Altered, retinal layer structure | |||||
AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous System Disease | Under Development | 0.25 | KE:352 | N/A, Neurodegeneration |
AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular System Disease | Under Development | 0.29 | KE:1847 | Increased SARS-CoV-2 production |
KE:1869 | Diminished protective oxidative stress response | |||||
AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.67 | KE:1115 | Increase, Reactive oxygen species |
KE:68 | Accumulation, Collagen | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | |||||
AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal System Disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.25 | KE:40 | Decrease, Mitochondrial ATP production |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:394 | SARS-CoV-2 infection of olfactory epithelium leading to impaired olfactory function (short-term anosmia) | Endocrine System Disease | Under Development | 0.14 | KE:1847 | Increased SARS-CoV-2 production |
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | 0.12 | KE:1821 | Decrease, Cell proliferation |
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:759 | Increased, Kidney Failure | |||||
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:870 | Increase, Cell Proliferation |
AOP:422 | Binding of SARS-CoV-2 to ACE2 in enterocytes leads to intestinal barrier disruption | Gastrointestinal System Disease | Under Development | 0.2 | KE:1847 | Increased SARS-CoV-2 production |
AOP:430 | Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation | Viral Infectious Disease | Under Development | 0.2 | KE:1847 | Increased SARS-CoV-2 production |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.36 | KE:155 | Inadequate DNA repair |
KE:870 | Increase, Cell Proliferation | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:403 | Suppression, Immune system | |||||
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.33 | KE:149 | Increase, Inflammation |
KE:1971 | Increased, tumor growth | |||||
KE:1262 | Apoptosis | |||||
AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System Disease | Under Development | 0.22 | KE:1052 | Hyperplasia, ovarian epithelium |
KE:1050 | Increased, secretion of LH from anterior pituitary | |||||
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1262 | Apoptosis |
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.2 | KE:155 | Inadequate DNA repair |
KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | |||||
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.14 | KE:352 | N/A, Neurodegeneration |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.44 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.09 | KE:1262 | Apoptosis |
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.17 | KE:317 | Altered, Cardiovascular development/function |
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
KE:2043 | Decrease, Sonic Hedgehog second messenger production | |||||
AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:2050 | Increase, developmental abnormalities |
AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities |
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.12 | KE:1493 | Increased Pro-inflammatory mediators |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.2 | KE:870 | Increase, Cell Proliferation |
KE:155 | Inadequate DNA repair | |||||
AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.2 | KE:40 | Decrease, Mitochondrial ATP production |
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
KE:2043 | Decrease, Sonic Hedgehog second messenger production | |||||
AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive System Disease | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.4 | KE:1633 | Increase in inflammation |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:2125 | Increased fat mass | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:518 | Liver X Receptor (LXR) activation leads to liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.2 | KE:89 | Synthesis, De Novo Fatty Acid (FA) |
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous System Disease | - | 0.17 | KE:149 | Increase, Inflammation |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:1262 | Apoptosis |
AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental Disorder Of Mental Health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:2195 | Increase, CNS Neural cell death |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | 0.12 | KE:864 | Decreased, Body Weight |
AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous System Disease; Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.25 | KE:341 | Impairment, Learning and memory |
KE:352 | N/A, Neurodegeneration | |||||
AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:341 | Impairment, Learning and memory |
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.3 | KE:1492 | Tissue resident cell activation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.15 | KE:89 | Synthesis, De Novo Fatty Acid (FA) |
KE:345 | N/A, Liver Steatosis | |||||
AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary System Disease | WPHA/WNT Endorsed | 0.6 | KE:827 | sensitisation, skin |
KE:826 | Activation, Keratinocytes | |||||
KE:272 | Activation/Proliferation, T-cells | |||||
AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | WPHA/WNT Endorsed | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:402 | Cognitive function, decreased | |||||
AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.22 | KE:341 | Impairment, Learning and memory |
KE:352 | N/A, Neurodegeneration | |||||
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:341 | Impairment, Learning and memory | |||||
AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive System Disease | - | 0.33 | KE:330 | Decrease, Fertility |
KE:807 | Decreased, cholesterol | |||||
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.22 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:402 | Cognitive function, decreased | |||||
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.5 | KE:885 | Increase, Cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory System Disease | Under Development | 0.25 | KE:1250 | Decrease, Lung function |
AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular System Disease | Under Development | 0.3 | KE:927 | KE1 : S-Glutathionylation, eNOS |
KE:952 | Hypertension | |||||
KE:933 | KE6 : Depletion, Nitric Oxide | |||||
AOP:151 | AhR activation leading to preeclampsia | Cardiovascular System Disease | Under Development | 0.14 | KE:1893 | increase, Preeclampsia |
AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory System Disease | - | 0.11 | KE:1226 | Increased Respiratory irritability and Chronic Cough, |
AOP:205 | AOP from chemical insult to cell death | Unclassified | - | 0.17 | KE:1262 | Apoptosis |
AOP:227 | NSAID induced PTGS1 inactivation to gastric ulcer | Gastrointestinal System Disease | - | 0.14 | KE:1385 | Activated, gastric ulcer formation |
AOP:228 | NSAID induced PTGS2 inactivation to gastric ulcer | Gastrointestinal System Disease | - | 0.2 | KE:1385 | Activated, gastric ulcer formation |
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.14 | KE:1514 | Neurodegeneration |
AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular System Disease | Under Development | 0.12 | KE:1535 | Heart failure |
AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development |
AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.25 | KE:1549 | Liver Injury |
KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | |||||
AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous System Disease | - | 0.1 | KE:352 | N/A, Neurodegeneration |
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.56 | KE:1193 | N/A, Breast Cancer |
KE:1492 | Tissue resident cell activation | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
KE:1494 | Leukocyte recruitment/activation | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.56 | KE:1193 | N/A, Breast Cancer |
KE:1492 | Tissue resident cell activation | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
KE:1494 | Leukocyte recruitment/activation | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | Under Development | 0.2 | KE:402 | Cognitive function, decreased |
AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory System Disease | Under Development | 0.2 | KE:1250 | Decrease, Lung function |
AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary System Disease | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1603 | Chronic kidney disease | |||||
AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | 0.6 | KE:1868 | Hyperinflammation |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive Disorder | - | 0.2 | KE:402 | Cognitive function, decreased |
AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.5 | KE:1868 | Hyperinflammation |
KE:1847 | Increased SARS-CoV-2 production | |||||
KE:1869 | Diminished protective oxidative stress response | |||||
AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory System Disease | - | 0.25 | KE:1250 | Decrease, Lung function |
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1250 | Decrease, Lung function | |||||
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:1250 | Decrease, Lung function |
KE:1262 | Apoptosis | |||||
AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory System Disease | - | 0.17 | KE:1250 | Decrease, Lung function |
AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory System Disease | - | 0.17 | KE:1250 | Decrease, Lung function |
AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited Metabolic Disorder | - | 0.4 | KE:1953 | Gestational diabetes mellitus |
KE:1952 | Abnormal, Glucose homeostasis | |||||
AOP:433 | hERG channel blockade leading to sudden cardiac death | Cardiovascular System Disease | - | 0.17 | KE:1964 | Sudden cardiac death |
AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive Disorder | Under Review | 0.14 | KE:402 | Cognitive function, decreased |
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.33 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:2119 | Insulin resistance, increased | |||||
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.12 | KE:402 | Cognitive function, decreased |
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.22 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:402 | Cognitive function, decreased | |||||
AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.5 | KE:1847 | Increased SARS-CoV-2 production |
KE:1868 | Hyperinflammation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental Disorder Of Mental Health | Under Development | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.25 | KE:1492 | Tissue resident cell activation |
KE:341 | Impairment, Learning and memory | |||||
AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.09 | KE:341 | Impairment, Learning and memory |
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.33 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |||||
KE:2135 | Prostate cancer | |||||
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.38 | KE:1115 | Increase, Reactive oxygen species |
KE:2145 | Metabolic syndrome | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous System Disease | - | 0.5 | KE:191 | Neuronal dysfunction |
KE:2150 | Neurological disorder | |||||
AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental Disorder Of Mental Health | - | 0.25 | KE:341 | Impairment, Learning and memory |
AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental Disorder Of Mental Health | - | 0.57 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:352 | N/A, Neurodegeneration | |||||
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.25 | KE:2150 | Neurological disorder |
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.2 | KE:341 | Impairment, Learning and memory |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.08 | KE:341 | Impairment, Learning and memory |
AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.17 | KE:341 | Impairment, Learning and memory |
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.22 | KE:1262 | Apoptosis |
KE:341 | Impairment, Learning and memory | |||||
AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular System Disease | - | 0.29 | KE:2261 | Decreased, blood plasma volume |
KE:1535 | Heart failure | |||||
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular System Disease | - | 0.2 | KE:1535 | Heart failure |
AOP:552 | Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) | Cardiovascular System Disease | - | 0.17 | KE:1535 | Heart failure |
AOP:553 | Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure | Cardiovascular System Disease | - | 0.25 | KE:1535 | Heart failure |
AOP:555 | Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure | Cardiovascular System Disease | - | 0.2 | KE:1535 | Heart failure |
AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular System Disease | - | 0.17 | KE:1535 | Heart failure |
AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular System Disease | - | 0.17 | KE:1535 | Heart failure |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.57 | KE:1492 | Tissue resident cell activation |
KE:68 | Accumulation, Collagen | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:244 | Alkylation, Protein | |||||
AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.25 | KE:486 | systemic inflammation leading to hepatic steatosis |
AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive System Disease | - | 0.2 | KE:642 | Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol |
AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary System Disease | Under Development | 0.09 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal System Disease | - | 0.38 | KE:1287 | Glutathione synthesis |
KE:1286 | Down Regulation, GSS and GSTs gene | |||||
KE:1285 | Up Regulation, Unsaturated fatty acid | |||||
AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary System Disease | Under Development | 0.4 | KE:40 | Decrease, Mitochondrial ATP production |
KE:244 | Alkylation, Protein | |||||
AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | 0.75 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.33 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal System Disease | Under Review | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1753 | Chronic reactive oxygen species | |||||
AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.4 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
KE:1919 | Increased, Cardiac Dysregulation | |||||
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.4 | KE:1262 | Apoptosis |
KE:149 | Increase, Inflammation | |||||
KE:1496 | Increased, secretion of proinflammatory mediators | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1250 | Decrease, Lung function | |||||
KE:1993 | Increase, Pneumonia | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
KE:1198 | Activation, Macrophages | |||||
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.15 | KE:1115 | Increase, Reactive oxygen species |
KE:1198 | Activation, Macrophages | |||||
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.15 | KE:1115 | Increase, Reactive oxygen species |
KE:1198 | Activation, Macrophages | |||||
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.06 | KE:1115 | Increase, Reactive oxygen species |
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.22 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.23 | KE:1115 | Increase, Reactive oxygen species |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:1198 | Activation, Macrophages |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.25 | KE:1633 | Increase in inflammation |
KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | |||||
KE:759 | Increased, Kidney Failure | |||||
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.36 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1262 | Apoptosis | |||||
KE:2034 | liver dysfunction | |||||
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.33 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:759 | Increased, Kidney Failure | |||||
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.43 | KE:1115 | Increase, Reactive oxygen species |
KE:1869 | Diminished protective oxidative stress response | |||||
KE:402 | Cognitive function, decreased | |||||
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.6 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:885 | Increase, Cancer | |||||
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.6 | KE:1115 | Increase, Reactive oxygen species |
KE:1060 | Alteration, lipid metabolism | |||||
KE:885 | Increase, Cancer |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.